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The Brugada syndrome (BrS) is a malignant, genetically-determined, arrhythmic syndrome manifesting as syncope or
sudden cardiac death (SCD) in individuals with structurally normal hearts. The diagnosis of the BrS is mainly based on
the presence of a spontaneous or Na + channel blocker induced characteristic, electrocardiographic (ECG) pattern (type
1 or coved Brugada ECG pattern) typically seen in leads V1 and V2 recorded from the 4th to 2nd intercostal (i.c.) spaces.
This pattern needs to be distinguished from similar ECG changes due to other causes (Brugada ECG phenocopies). This
review focuses mainly on the ECG-based methods for diagnosis and arrhythmia risk assessment in the BrS. Presently,
the main unresolved clinical problem is the identification of those patients at high risk of SCD who need implantable
cardioverter-defibrillator (ICD), which is the only therapy with proven efficacy. Current guidelines recommend ICD
implantation only in patients with spontaneous type 1 ECG pattern, and either history of aborted cardiac arrest or
documented sustained VT (class I), or syncope of arrhythmic origin (class IIa) because they are at high risk of recurrent
arrhythmic events (up to 10% or more annually for those with aborted cardiac arrest). The majority of BrS patients are
asymptomatic when diagnosed and considered to have low risk (around 0.5% annually) and therefore not indicated for
ICD. The majority of SCD victims in the BrS, however, had no symptoms prior to the fatal event and therefore were not
protected with an ICD. While some ECG markers such as QRS fragmentation, infero-lateral early repolarisation, and
abnormal late potentials on signal-averaged ECG are known to be linked to increased arrhythmic risk, they are not
sufficiently sensitive or specific. Potential novel ECG-based strategies for risk stratification are discussed based on
computerised methods for depolarisation and repolarisation analysis, a composite approach targeting several major
components of ventricular arrhythmogenesis, and the collection of large digital ECG databases in genotyped BrS
patients and their relatives.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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The Brugada syndrome (BrS) is a malignantarrhythmia syndrome manifesting as recur-
rent syncope or sudden cardiac death (SCD) due
to polymorphic ventricular (VT) or ventricular
fibrillation (VF) in the absence of overt structural
heart disease or myocardial ischemia [1,2]. The
prevalence of the syndrome is estimated at
around 15 per 10,000 in South East Asia, including
Japan and around 2 per 10,000 in the Western
countries [3,4]. One study on a southern Turkish
population suggested that the prevalence of BrS
in the Middle East may be lower than in South
East Asia and higher than in the West [5]. The
BrS may be responsible for up to 4% of all sudden
cardiac deaths (SCD) and at least 20% of SCDs in
patients with structurally normal hearts [6]. It is
eight to ten times more prevalent in males than
in females [7]. In South East Asia, the BrS is the
leading cause of non-traumatic death in men
younger than 40 years [8]. The purpose of this arti-
cle is to briefly summarise current knowledge
about the electrocardiography (ECG) based
methods for diagnosis and assessment of the risk
of malignant arrhythmias in patients with the
BrS. Before that, the cellular and genetic mecha-
nisms of the BrS are discussed briefly.Genetics and cellular mechanisms
BrS has been considered a heritable autosomal
dominant disease [9] and more than 390 mutations
have been identified in the SCN5A gene encoding
the a-subunit of the cardiac INa-channel [10].
However, presently SCN5A mutations are found
only in 11–37% of the genotyped patients [11,12].
Many patients with the BrS have no family his-
tory, presumably due to under-diagnosis in other
family members, low penetrance, or sporadic
disease [13]. Recent data has suggested that heri-
tability may not be strictly monogenic, but may
in fact relate to common genetic variation [14].The cellular basis of the BrS is still not com-
pletely clear [15]. According to the repolarisation
theory, genetically determined or drug-induced
reduction of the inward Na+ current leads to
unopposed transient outward (Ito) current in some
(but not all) epicardial regions of the right ventric-
ular outflow tract (RVOT), which causes either
delayed expression of the action potential (AP)
dome and epicardial AP prolongation or loss of
the dome and AP shortening. The net effect is
magnification of repolarisation dispersion
between the RVOT endo- and epicardium, and
between different RVOT epicardial regions, which
is potentially arrhythmogenic. The repolarisation
theory was initially promoted on the basis of
experimental studies [16–18]. It was later sup-
ported by clinical studies, which demonstrated a
‘spike and dome’ configuration with deep notch-
ing of monophasic action potentials (MAP) from
the RVOT epicardium but not endocardium [19],
paradoxical shortening of the RVOT epicardial
activation-recovery intervals (ARI) during aug-
mentation of Brugada-type ST segment elevation
Figure 2. Resting ECG in a 45-year-old asymptomatic man with BrS,
with simultaneous recording of leads V1 and V2 from the 4th, 3rd and
2nd intercostal (i.c.) space (leads V1, V2, V13, V23, V12 and V22,
respectively) as well as lead V3 in standard position and one (V33)
and two (V32) i.c. spaces higher. Note that for all three leads (V1, V2
and V3), Brugada type 1 pattern appears either only or more clearly
in the ‘high’ positions (3rd and 2nd i.c. spaces) compared to their
standard locations. For example, lead V3 shows no Brugada type
pattern in the standard position, clear type 2 pattern is one i.c. space
higher, and marked type 1 pattern, when the electrode is moved, is
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the RVOT[21–23] (both clinically and experimen-
tally), and longer ARI in the RVOT epicardium
recorded from the conus branch of the right coro-
nary artery than in the endocardium of patients
with BrS and type 1 ECG pattern, but not in
controls [24].
There is also mounting evidence from experi-
mental [22], histopathological [25], computational
[25], clinical electrophysiological [23,26], and
imaging [27] studies for the presence of conduc-
tion abnormalities in the RVOT and their impor-
tance for the genesis of ventricular arrhythmias
in BrS [22,23] (depolarisation theory). A mecha-
nism explaining the Brugada ECG type solely by
delay of the RVOT activation relative to the rest
of the RV has also been proposed [28]. The pres-
ence of late potentials and prolonged filtered
QRS duration on signal-averaged ECG (SAECG)
as well as increased notching and fragmentation
of the QRS on the standard ECG are linked to
increased arrhythmic risk in BrS [29–32]. A third
hypothesis unifying the above two explains the
BrS with abnormal expression of the neural crest
cells during the embryological development of
the RVOT. This defect in the embryogenesis of
the RVOT leads to both abnormally augmented
electrical gradients during repolarisation as well
as to delayed activation of the RVOT [33].
From the electrocardiographic point of view, the
characteristic elevation of the J point and ST
segment of the diagnostic Brugada type 1 pattern
(see below) results from early relative (intracellu-
lar) positivity of the unaffected zone (RVOTFigure 1. Leads V1–V3 from a resting 12 lead ECG in a 32-year-old
man with the BrS. Note the typical type 1 pattern in leads V1 and V2
and type 2 patterns in lead V3. In this one and in all subsequent
figures, ECGs are displayed at 25 mm/s, 1 cm/mV, unless stated
otherwise. All ECGs presented on this one and all subsequent figures
have been originally acquired with high-pass filter of 0.05 Hz.
Figure 3. Snapshot from a positive diagnostic ajmaline test in an
asymptomatic 50-year-old man with BrS and non-diagnostic resting
12-lead ECG. Lead V1 and V2 leads from the 3rd and 2nd i.c. space
were not recorded because the test was performed before the
diagnostic value of the ‘high’ right precordial leads was established.
The ECG on the figure was recorded four minutes after the start of the
test. The standard unipolar lead V2 still displays non-diagnostic type
2 pattern, whereas the bipolar leads between the V2 electrode
(positive pole) and V4, V5 or V6 electrode (leads V2_4, V_5, V2_6,
respectively) display typical type 1 pattern. One minute later,
diagnostic type 1 pattern appeared in lead V2 as well (not shown).
Figure 4. Type 2 (lead V2) and type 3 (lead V1) Brugada ECG
pattern. Note that both ECG patterns are characterised by the same
general shape of the J-ST-T wave, but the ST segment elevation in
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theory or normally activated myocardium outside
the RVOT according to the depolarisation theory),
whereas the negative T wave is an expression of
late epicardial relative (intracellular) positivity in
the affected RVOT zone, due to either prolonga-
tion of the epicardial APs or its delayed activation.Clinical manifestations
The symptoms associated with the BrS are due
to re-entry ventricular arrhythmias typically aris-
ing in the affected zone of the RV. If they last
briefly (seconds) and terminate spontaneously
they can be asymptomatic or cause palpitations,
syncope or nocturnal agonal respiration, or canFigure 5. ECGs recorded at baseline (left panel) and six minutes after the
an asymptomatic 35-year-old man who was investigated because his restin
of the BrS. In both panels, the leads from top are V1, V2, V3 and V1 from 3
one i.c. space higher than the standard position (lead V33). Note the pres
subsequently converted to typical type 1 pattern following ajmaline admini
whereas in lead V2, the normal ECG configuration is transformed by thedegenerate into VF and lead to cardiac arrest.
Since the duration of the arrhythmia is unpredict-
able and every arrhythmic episode can be fatal,
the assessment of the degree of arrhythmic risk
and the need for prophylactic treatment is by far
the most important aspect of the management of
these patients (see below).Electrocardiographic diagnosis of the
Brugada syndrome
The diagnostic hallmark of the BrS is a charac-
teristic ECG pattern consisting of J point elevation
with slowly descending or concave ST segment
elevation merging into a negative or reaching the
isoelectric line symmetric T wave, described as
‘coved’ or type 1 Brugada ECG pattern [7,34]
(Fig. 1). Most frequently, it is observed in leads
V1 and V2 (less frequently in V3 [35]) especially
when recorded from the 3rd or 2nd intercostal
(i.c.) space [36] (Fig. 2) but sometimes it can be
observed in the inferior [37–40] or lateral [41,42]
leads (atypical BrS). One study found that bipolar
precordial leads between the V2 electrode (posi-
tive pole) and V4 or V5 electrodes (negative pole)
computed from the standard unipolar leads V2,
V4 and V5 are more sensitive and equally specific
compared to lead V2 for detecting of Brugada type
1 pattern (Fig. 3) [43].
Another ECG pattern of J point and ST segment
elevation with a positive T wave in the right pre-
cordial leads, the so-called saddle-back pattern,start of diagnostic ajmaline test (right panel) with positive outcome in
g ECG (acquired for different reasons) had shown changes suspicious
rd i.c. space (lead V13), V2 from 3rd i.c. space (lead V23) and V3 from
ence of type 2 pattern in lead V2 (3rd i.c. space) at baseline which is
stration. During the test, type 1 pattern is also seen in lead V1 (3rd i.c.)
drug into type 2 pattern.
Figure 6. Examples of typical type 1 Brugada ECG pattern with (left panel) and without QRS notching/fragmentation. Lead V1 from the 4th, 3rd
and 2nd i.c. space is shown. (A) Fractionated QRS complex in a 25-year-old asymptomatic male patient with BrS (ajmaline-induced type 1
Brugada ECG pattern); (B) Spontaneous type 1 Brugada ECG pattern in a 53-year-old man with aborted cardiac arrest, implanted ICD, and
subsequently multiple appropriate shocks of the device. No considerable fractionation of the QRS complex can be seen. See the text for details.
The examples above suggest that although the presence of QRS notching/fragmentation is linked to increased risk of sudden cardiac death in the







Figure 7. (A) A signal-averaged ECG (SAECG) with abnormal late potentials in a 60-year-old man with no previous history of arrhythmic
symptoms and spontaneous type 1 Brugada ECG pattern. The total filtered QRS duration, the duration of the high frequency low amplitude
(HFLA) <40 lV and the root-mean-square voltage (RMS) in the terminal 40 ms of the QRS are 137 ms, 55 ms and 15 lV, respectively (all three
parameters are abnormal). The noise level is 0.25 lV, the number of averaged complexes is 214 and the filter settings are 40–240 Hz. (B) Resting
ECG of the same patient. Only lead V1–V3 from 4th to 2nd i.c. space are shown. Note the presence of typical type 1 Brugada ECG pattern in
many leads, with QRS fractionation in leads V1 (4th and 3rd i.c. space) and V2 (3rd and 2nd i.c. space). Note also that the type 1 Brugada pattern
generally becomes more pronounced when moving the recording electrodes cranially from 4th to 2nd i.c. space (it is present even in lead V3 when
recorded 2 i.c. spaces higher (lead V32), which is a relatively rare finding).
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The saddle back patterns are further divided into
type 2 and type 3 Brugada ECG pattern, depend-
ing on the level of J point and ST segment
elevation (Fig. 4). A recently published expertconsensus report on the ECG characteristics of
the BrS [34] proposed type 2 and type 3 patterns
to be unified into one saddle-back Brugada pat-
tern because, according to the authors’ opinion,
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significance. In the latest HRS/EHRA/APHRS
Expert Consensus Statement on the Diagnosis
and Management of Patients with Inherited
Primary Arrhythmia Syndromes published in
December 2013 [7], however, type 2 and type 3
Brugada ECG patterns are mentioned separately.
Up to 40% of patients with the BrS present with
normal or non-diagnostic, resting ECG [44]. In
these patients, the diagnostic ‘coved’ ECG pattern
can be elicited by IV administration of sodium
channel blocker (ajmaline, procainamide, flecai-
nide) [45,46] (Fig. 5). It is important to distinguish
between type 2 Brugada ECG pattern and the
r0-pattern (incomplete right bundle branch block
(IRBBB) pattern) in leads V1 and V2 (especially
when recorded from the 3rd or 2nd i.c. space),
which can be observed in healthy subjects, and
frequently in athletes [47]. It has been reported
that a broader angle between the ascending and
descending limb of the r0-wave [48] or a broader
base of the triangle formed by the two limbs of
the r0-wave measured at 5 mm from the highest
point [49,50] can reliably distinguish type 2
Brugada ECG pattern from IRBBB pattern.
Currently, the diagnosis of BrS is definite when
type 1 pattern is observed in at least one of leads
V1 and V2 recorded from the 4th, 3rd or 2nd i.c.
space, either spontaneously or following adminis-
tration of Na+ channel [7]. The presence of gene
mutations is not considered essential for the
diagnosis [2,7].
The classical diagnostic type 1 Brugada ECG
pattern needs to be distinguished from similar
Brugada-like patterns caused by atypical right
bundle branch block, septal hypertrophy, arrhyth-
mogenic right ventricular cardiomyopathy
(ARVC), pectus excavatum and other conditions,
and also from the transient appearance of the typ-
ical Brugada pattern in the cause of various acute
processes such as acute ischaemia, Prinzmetal
angina, pulmonary embolism, pericarditis, meta-
bolic disorders, various medications and others
(the so-called Brugada phenocopies) [51].
The use of inappropriate high-pass filters dur-
ing ECG acquisition (e.g. non-linear phase, high-
pass filter of 0.5 Hz instead of the recommended
0.05 Hz) [52] can cause considerable ST segment
distortion which can mimic type 1 or 2 Brugada
pattern [34,53,54].
The ECG in BrS shows considerable dynamic
variability; it can be completely normal at one time
and demonstrate diagnostic type 1 pattern at
another [55]. Vagal influences (slow heart rate,
postprandial state, night-time) tend to augmentthe J point and ST segment elevation and the type
1 pattern [56], whereas exercise and catecholamine
infusion have the opposite effect (in selected BrS
patients the ST segment elevation might become
more prominent during exercise) [57]. Autonomic
influences also play important roles in the genesis
of malignant arrhythmias because most arrhyth-
mic events in BrS occur at night [2], and long RR
intervals often precede episodes of VT/VF [58],
whereas catecholamine infusion is used as a first
line treatment of such episodes [59]. Patients with
BrS have increased incidence (10–53%) of atrial
fibrillation (AF) [60,61].
In asymptomatic patients with spontaneous or
induced by Na-channel blockers type 1 pattern,
the diagnosis of BrS is supported by the presence
of atrial fibrillation, atrio-ventricular or intraven-
tricular conduction abnormalities (first degree
A-V block, left axis deviation of the QRS complex,
fragmented QRS (Fig. 6), late potentials on the
signal-averaged ECG (SAECG) (Fig. 7), HV
interval >60 ms), ventricular ectopic beats with left
bundle branch block (LBBB) morphology, and
short (<200 ms) ventricular effective refractory
period during electrophysiology study (EPS) [7].Risk stratification – the most important
clinical problem in the Brugada syndrome
Currently, this is by far the most important and
yet unresolved clinical problem in the BrS. It is
similar to one of the main (and also unresolved)
problems of modern cardiology – the identifica-
tion of patients with ischaemic heart disease
(IHD) at high risk of dying suddenly who need a
prophylactic implantable cardioverter-defibrilla-
tor (ICD).
In BrS patients with a previous history of
arrhythmic syncope or aborted cardiac arrest, the
annual event rate of sustained VT or VF is rela-
tively high – between 1.9% [62] and 8.8% [63],
and between 7.7% [62] and 13.8% [63], respec-
tively. They are indicated for ICD, which is the
single therapy with proven efficacy (class I indica-
tion for those with aborted cardiac arrest or
spontaneous sustained VT and class IIa for those
with syncope) [7]. However, the majority of BrS
patients (64% in the largest reported series of
1029 BrS patients, the FINGER study [62]) have
no symptoms at the time of establishment of diag-
nosis. The annual rate of SCD or sustained VT in
these patients is low – between 0% [64,65] and
0.8 [66] (0.5% in the FINGER study [62], 0.4–1%
in three Japanese studies [67–69]) and cannot jus-
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ally normal hearts and are young or middle aged
when diagnosed (median age 45 years in the
FINGER study), and therefore the low annual risk
translates into considerable cumulative arrhyth-
mic risk for the next several decades of their life
expectancy. In fact, the majority of victims of
SCD in BrS come from this ‘low risk’ (according
to current standards) population. Among patients
with the BrS who have died suddenly, 68% had no
previous history of arrhythmia-related symptoms
and therefore had not been protected by ICD
[13]. Currently, there are no reliable methods for
identification of these patients (see below). Simi-
larly, the largest absolute number of patients with
IHD who die suddenly also comes from a patient
population considered to have low risk (i.e. with
relatively preserved ejection fraction) [70].
On the other hand, the decision to offer an ICD
even to a BrS patient with a syncope is often diffi-
cult because unlike IHD patients, most of them
are relatively young, apparently healthy, and
without any previous awareness of cardiac prob-
lems. In addition, it is often very difficult to
exclude non-arrhythmic cause of the syncope.
Finally, the rate of ICD-related complications
(20–30% annually including inappropriate shocks)
is higher than the rate of appropriate activation of
the device (2.6–8% annually) [71–73]. This suggests
that novel, better methods of risk-stratification are
needed even in the group of patients with cur-
rently accepted indications for ICD therapy (those
with aborted cardiac arrest or syncope).
Problems with current methods of risk
stratification in the BrS
While two studies [74,75] reported increased
occurrence of arrhythmic events in BrS patients
with SCN5A mutations, these findings have not
been confirmed by other studies [76,77]. Some
specific mutations or common single-nucleotide
polymorphism (SNP) might have prognostic sig-
nificance [7]. The genetic analysis is expensive,
time-consuming, and available only in specialised
centres. Male gender [11] and presence of AF
[60,61] are linked to increased risk of malignant
ventricular arrhythmias. The role of programmed
ventricular stimulation (PVS) during EPS for
induction of VT and/or assessment of the ventric-
ular effective refractory period for the purpose of
risk stratification have been an object of contro-
versy and debate since the first descriptions of
the BrS. While some studies support its value for
risk stratification mainly due to its high negative
predictive value [78,79], most recent studies havefailed to confirm its independent predictive value
[80,81,71]. Likewise, in the FINGER study [62],
inducibility during EPS did not predict arrhythmic
events in multivariate analysis, whereas in the
multicentre PRELUDE study which tested uni-
form protocol of PVS during EPS in all 308
patients, the rate of arrhythmic events during an
average follow-up of three years showed no differ-
ence between the 126 inducible (3.9%) and the 182
non-inducible patients (4.9%) [82]. Currently, its
role of EPS for risk stratification is accepted only
as a Class IIb (‘may be considered’) indication
[7,83]. The method is inherently limited by its
invasive character and probably also by the labile
nature of the underlying electrophysiologic sub-
strate [84].ECG-based methods for risk stratification
Apart from the spontaneous (as opposed to
drug-induced) appearance of the diagnostic type
1 pattern, currently no other ECG feature has con-
sistently shown an indication for increased
arrhythmic risk.
In contrast with acute myocardial infarction
(MI), the number of leads displaying type 1 pat-
tern and the degree of J point or ST-segment ele-
vation do not seem to correlate with the
arrhythmic risk [35,36]. The high (3rd or 2nd i.c.
space) positions of leads V1 and V2 are diagnosti-
cally more sensitive than their standard positions
in the 4th i.c. space [85–87], but, prognostically,
their value is the same [88]. Similar to other dis-
eases with intraventricular conduction abnormali-
ties such as IHD and cardiomyopathies, the
presence of notched or fragmented QRS [82,32],
(Fig. 6) and abnormal late potentials on the sig-
nal-averaged ECG (SAECG) [31] (Fig. 7) seems to
indicate increased arrhythmic risk in the BrS.
However, currently, the presence of notching/
fractionation is assessed only visually with arbi-
trary descriptive terms (e.g. number of QRS
peaks). The role of the standard time-domain
SAECG in BrS is limited by (a) inability to detect
conduction abnormalities within the QRS complex,
(b) uncertain value in patients with bundle branch
block, and (c) the use of a single-lead ECG com-
plex, which is derived from the XYZ orthogonal
leads and does not contain any regional informa-
tion. Limited data suggest that a number of ECG
parameters may indicate BrS patients at higher
risk of malignant arrhythmias: changes in repolar-
isation dynamics (QT/RR and Tpeak  Tend/RR
intervals relations); [89] deep negative T wave in
lead V1; [90] QTc interval more than 460 ms in
Figure 8. Principal component analysis (PCA) of the ST-T wave
(from the J point to the end of the T wave) in the right precordial leads
of ECGs recorded during diagnostic ajmaline test. (A) Positive
ajmaline test in a 15-year-old girl with the BrS and a past history of
syncope of presumable arrhythmic origin. (B) Negative ajmaline test
in a 67-year-old asymptomatic man with a family history of BrS and
sudden cardiac death. Each bar represents the PCA value (ratio of the
2nd/1st eigenvalue) from analysis of one 10-s ECG recording. Two to
five 10-s ECGs were recorded during the test. On the X-axis, time is
shown in minutes from the beginning of the test. ECGs were recorded
at baseline (b) as well as up to 15 min after the start of the drug
administration. PCA has been applied to the V1–V3 leads (blue
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dynamic alterations in the amplitude of the ST
elevation; [92] presence of infero-lateral early
repolarisation; [93,94] the presence of horizontal
(as opposed to rapidly ascending) ST segment
after the J point; [68] prolonged PR-interval; [90]
the presence of atrial arrhythmias; [95] and aug-
mentation of the ST segment elevation during
the early recovery phase of exercise test [96].
However, none of the above ECG-based param-
eters has consistently shown sufficiently high risk
predictive value. As a result, currently the only
class I indications for ICD implantation (‘ICD is
recommended’) in patients diagnosed with the
BrS endorsed by the 2013 HRS/EHRA/APHRS
Expert Consensus Statement [7] is history of
aborted cardiac arrest or documented spontaneous
sustained VT (with or without syncope). The
Consensus Statement-endorsed history of syncope
is judged to be likely caused by ventricular
arrhythmias only as a Class IIa indication (‘ICD
can be useful’) which reflects the difficulty of
excluding a non-cardiac origin of syncope. The
guidelines of the Japanese Cardiac Society of
2011 accept practically the same Class I indications,
whereas for Class IIa indications they require the
presence of at least two of the following risk factors:
history of syncope, family history of sudden
cardiac death, and inducible VF during EPS [97].
In summary, the current indications for ICD
implantation in the BrS are based solely on the
presence of arrhythmia-related symptoms, spon-
taneous appearance of type 1 (‘coved’) Brugada
ECG pattern and, in some institutions, inducibility
of sustained VT/VF during EPS. While studies
have demonstrated the link between several
ECG parameters and increased arrhythmic risk,
none of these parameters seem to possess consis-
tent and sufficient sensitivity, specificity and pre-
dictive value to be used as a risk-stratifier in the
BrS. As a result, an unknown number of asymp-
tomatic BrS patients are likely to experience their
first and potentially lethal arrhythmic event with-
out being protected by ICD. Therefore, there is a
pressing need to develop new, sufficiently sensi-
tive and specific, easily applicable methods for
risk stratification in the BrS. ECG-based methods
seem to be the most suitable for this task.diamonds). Data are presented as mean ± standard deviation (SD) of
all complexes within one 10-s ECG. Generally, higher values reflect
more heterogeneous (and, hence, more abnormal and potentially more
arrhythmogenic) ventricular repolarisation. The figures show that the
appearance of diagnostic type 1 Brugada ECG pattern during the
positive test (A) is accompanied by a striking increase in the PCA
ratio, whereas during a negative test, there is practically no change in
PCA (the SD deviation bars are hidden within the diamond bars).
Adapted from [100].ECG-based methods for risk stratification
in the BrS – some suggestions for future
directions
Obvious obstacles to the development of novel
methods for risk stratification in the BrS are thelow rate of arrhythmic events (i.e. endpoint events
in prospective follow-up), the small number of
patients in the individual centres (since the prev-
alence of the disease outside South East Asia is
generally low), difficult organisation of big multi-
centre prospective studies and, possibly, inherent
Figure 9. PCA of the QRS complex of leads V1–V3 from the 3rd i.c.
space recorded during positive ajmaline test in patients with previous
history of arrhythmia-related symptoms (n = 6, brown bars), during
positive ajmaline test in asymptomatic patients (n = 17, yellow bars)
and in patients with negative ajmaline tests (n = 73, blue bars). Data
are presented as mean ± standard error (SE) of all ECG complexes
recorded during one minute of the tests as well as at baseline. Note the
distinctly different pattern of PCA of the QRS in symptomatic and
asymptomatic BrS patients with positive ajmaline test. In the latter
group, PCA of the QRS is similar to those with negative ajmaline
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(e.g. Western vs. Japanese [66]).
In our view, another, less appreciated obstacle is
the fact that currently ECG research studies (as
well as everyday clinical practice) generally still
use 12-lead paper ECGs (or digital ECG images),
which are amenable only to visual assessment
and simple manual measurement. Over the last
decades, computerised mathematical methods
for quantitative assessment of QRS and ST-T
wave abnormalities have been developed and suc-
cessfully tested in various cardiac diseases [98,99],
but they require the availability of digital ECGs
(digital files containing the raw ECG signal and
not just digital image files). Small pilot studies
have already shown the potential usefulness of
some methods for arrhythmia risk stratification
in the BrS, but they need to be tested prospec-
tively in larger populations.
Principal component analysis (PCA) is a known
method for quantitative assessment of depolarisa-
tion and repolarisation heterogeneity with estab-
lished diagnostic and prognostic value in
patients with different cardiac diseases [98]. PCA
of the ST-T wave can detect increased repolarisa-
tion heterogeneity and help establish the diagno-
sis in patients with suspected BrS and non-
diagnostic resting ECGs (Fig. 8) [100], whereas
PCA of the QRS complex has been shown to have
prognostic value (Fig. 9) [101].
A small pilot study on genotyped BrS patients
demonstrated that wavelet transform (WT) of the
QRS complex and ST-T wave of leads V1 and V2leads from the 2nd and 3rd i.c. space can distin-
guish patients with mutations (n = 12) from those
without mutations (n = 14) [102]. WT is particu-
larly suitable for analysis of time-varying, quickly
changing signals such as the QRS complex and
the interval around the J point where the main
events in BrS take place.
Therefore, the development of novel ECG-based
risk stratification approaches in the BrS requires
the collection of a large high-quality databases of
digital ECGs acquired in genotyped symptomatic
and asymptomatic patients with the BrS and their
relatives both at rest as well as continuously dur-
ing dynamic conditions (exercise stress test,
ambulatory conditions, pharmacologic testing
with Na+ channel blockers). Preferably, leads V1
and V2 should be recorded simultaneously in both
the standard as well as higher positions (4th, 3rd
and 2nd i.c. spaces) since the anatomic relation
between the RV and the electrode positions is
individually specific, and any of the three inter-
costal spaces could be closest to the RVOT [103].
Finally, the development of sustained VT/VF in
the BrS is likely a complex event resulting from
interaction between the arrhythmic substrate
(repolarisation and depolarisation abnormalities)
and various triggering and modifying factors
(e.g. ventricular ectopic beats, atrial arrhythmias,
autonomic modulations such as vagal surge, fever,
etc.) [22,15,104]. A successful ECG-based risk
stratification in BrS approach, therefore, should
likely involve the combined quantitative assess-
ment of several of the most important elements
of arrhythmogenesis. For example, one possible
composite approach could involve:
(a) Assessment of QRS heterogeneity (PCA, WT,
possibly other methods) and repolarisation
heterogeneity (PCA) in the right precordial
leads;
(b) Assessment of the spontaneous (continuous
rest ECG, Holter recordings) or induced (by
graded exercise, autonomic or pharmaco-
logic provocations) variability of depolarisa-
tion and repolarisation (variability of the
parameters identified in presence of micro-
volt T wave alternans, etc.);
(c) Assessment of cardiac autonomic control
(heart rate variability, heart rate turbulence,
etc.) from ambulatory Holter recordings or
short-term continuous recordings.
Conclusions
While the diagnosis of the BrS is relatively
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patients at high risk of dying suddenly who need
ICD implantation is still a largely unresolved
problem. With the current methods for risk strat-
ification, the majority of potential victims of SCD
remain unidentified and hence unprotected by
ICD before the fatal event. While some ECG
markers of depolarisation and repolarisation
abnormalities are known to be linked to increased
arrhythmic risk, their sensitivity or specificity
seems low, and they have not been tested in large
prospective studies. The development of novel
ECG-based methods for risk stratification would
likely require the availability of large digital ECG
databases in patients with BrS and their relatives,
application of new computerised methods for
quantitative assessment of depolarisation and
repolarisation abnormalities, and the design of
composite risk-stratification approaches targeting
all major elements of ventricular arrhythmogene-
sis in the BrS.References
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